News

Company News & Events

ORYZON Reports Financial Results and Corporate Update for the 4thQuarter and Year Ended December 31, 2018

15 February 2019

MADRID, SPAIN and CAMBRIDGE MA.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the fourth quarter of 2018 and provided an update on the Company's recent developments.

 

Click here to see the full Press Release

 

Posted In: 
News
Investors

Share this story